Bobby L. Clark

1.2k total citations
27 papers, 886 citations indexed

About

Bobby L. Clark is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Bobby L. Clark has authored 27 papers receiving a total of 886 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Bobby L. Clark's work include Cancer therapeutics and mechanisms (3 papers), Neuroendocrine Tumor Research Advances (3 papers) and Complementary and Alternative Medicine Studies (3 papers). Bobby L. Clark is often cited by papers focused on Cancer therapeutics and mechanisms (3 papers), Neuroendocrine Tumor Research Advances (3 papers) and Complementary and Alternative Medicine Studies (3 papers). Bobby L. Clark collaborates with scholars based in United States, United Kingdom and South Africa. Bobby L. Clark's co-authors include John D. Hainsworth, David R. Spigel, Howard A. Burris, Gail Hughes, Robert C. Whorf, David Waterhouse, Ian Duncan, Cassie M. Lane, Geraint Lewis and Thandi Puoane and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Cardiology.

In The Last Decade

Bobby L. Clark

26 papers receiving 839 citations

Peers

Bobby L. Clark
Ghada N. Farhat United States
Paul Carter United Kingdom
Ming-Chih Chou Taiwan
Mara M. Epstein United States
Lingyi Lu United States
Ahmet Özet Türkiye
Raquel E. Reinbolt United States
Li‐Ju Chen Taiwan
Mandana Kamgar United States
John Soong Singapore
Ghada N. Farhat United States
Bobby L. Clark
Citations per year, relative to Bobby L. Clark Bobby L. Clark (= 1×) peers Ghada N. Farhat

Countries citing papers authored by Bobby L. Clark

Since Specialization
Citations

This map shows the geographic impact of Bobby L. Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bobby L. Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bobby L. Clark more than expected).

Fields of papers citing papers by Bobby L. Clark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bobby L. Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bobby L. Clark. The network helps show where Bobby L. Clark may publish in the future.

Co-authorship network of co-authors of Bobby L. Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Bobby L. Clark. A scholar is included among the top collaborators of Bobby L. Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bobby L. Clark. Bobby L. Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hughes, Gail, et al.. (2021). Cost of Traditional Herbal Medicines for Noncommunicable Diseases in Rural and Urban Communities in South Africa. Value in Health Regional Issues. 29. 66–75. 5 indexed citations
2.
Clark, Bobby L., et al.. (2016). The Impact of a Worksite-Based Diabetes Prevention Intervention: A Pilot Study. Population Health Management. 20(3). 233–238. 4 indexed citations
3.
Clark, Bobby L., et al.. (2014). Evaluation of Increased Adherence and Cost Savings of an Employer Value-Based Benefits Program Targeting Generic Antihyperlipidemic and Antidiabetic Medications. Journal of Managed Care Pharmacy. 20(2). 141–150. 19 indexed citations
4.
Clark, Bobby L., John Hou, Chiahung Chou, Elbert S. Huang, & Rena M. Conti. (2014). The 340B Discount Program: Outpatient Prescription Dispensing Patterns Through Contract Pharmacies In 2012. Health Affairs. 33(11). 2012–2017. 14 indexed citations
5.
Hughes, Gail, et al.. (2013). The prevalence of traditional herbal medicine use among hypertensives living in South African communities. BMC Complementary and Alternative Medicine. 13(1). 38–38. 63 indexed citations
6.
Yardley, Denise A., Howard A. Burris, Bobby L. Clark, et al.. (2011). Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Breast Cancer. 11(3). 146–152. 24 indexed citations
7.
Spigel, David R., F. Anthony Greco, Howard A. Burris, et al.. (2011). A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer. 12(3). 187–191. 9 indexed citations
8.
Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2010). Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 28(13). 2131–2136. 135 indexed citations
9.
Spigel, David R., John D. Hainsworth, Victor G. Gian, et al.. (2010). A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 862–866. 4 indexed citations
10.
Hainsworth, John D., Jeffrey R. Infante, David R. Spigel, et al.. (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma. Cancer. 116(17). 4122–4129. 62 indexed citations
11.
Spigel, David R., John D. Hainsworth, Cassie M. Lane, et al.. (2010). Phase II Trial of Vinflunine in Relapsed Small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 874–878. 10 indexed citations
12.
Hainsworth, John D., David R. Spigel, Bobby L. Clark, et al.. (2010). Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site. The Cancer Journal. 16(1). 70–75. 46 indexed citations
13.
14.
Spigel, David R., F. Anthony Greco, Anthony A. Meluch, et al.. (2010). Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction. Journal of Clinical Oncology. 28(13). 2213–2219. 37 indexed citations
15.
16.
Hughes, Gail, et al.. (2009). Demographics and outcomes at American Society for Metabolic and Bariatric Surgery Centers of Excellence. Surgical Endoscopy. 23(4). 795–799. 64 indexed citations
17.
Yardley, Denise A., Howard A. Burris, David R. Spigel, et al.. (2009). A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer. Clinical Breast Cancer. 9(4). 247–252. 12 indexed citations
18.
Taylor, Herman A., Bobby L. Clark, Robert J. Garrison, et al.. (2005). Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. The American Journal of Cardiology. 95(3). 401–404. 41 indexed citations
19.
Flack, John M., et al.. (2003). From 1960s Evans County Georgia to Present-Day Jackson, Mississippi: An Exploration of the Evolution of Cardiovascular Disease in African Americans. The American Journal of the Medical Sciences. 325(6). 307–314. 11 indexed citations
20.
Dubbert, Patricia M., Teresa Carithers, John E. Hall, et al.. (2002). Obesity, Physical Inactivity, and Risk for Cardiovascular Disease. The American Journal of the Medical Sciences. 324(3). 116–126. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ghada N. Farhat Breakdown of academic impact, for papers by Paul Carter Breakdown of academic impact, for papers by Ming-Chih Chou Breakdown of academic impact, for papers by Mara M. Epstein Breakdown of academic impact, for papers by Lingyi Lu Breakdown of academic impact, for papers by Ahmet Özet Breakdown of academic impact, for papers by Raquel E. Reinbolt Breakdown of academic impact, for papers by Li‐Ju Chen Breakdown of academic impact, for papers by Mandana Kamgar Breakdown of academic impact, for papers by John Soong
Rankless by CCL
2026